Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors

被引:74
作者
Walter, H
Schmidt, B
Korn, K
Vandamme, AM
Harrer, T
Überla, K
机构
[1] Univ Erlangen Nurnberg, Inst Klin & Mol Virol, D-8520 Erlangen, Germany
[2] Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium
[3] Univ Erlangen Nurnberg, Inst Klin Immunol & Rheumatol, Med Klin 2, D-8520 Erlangen, Germany
[4] Univ Leipzig, Inst Virol, D-04103 Leipzig, Germany
关键词
HIV; antiretroviral therapy; resistance;
D O I
10.1016/S1386-6532(99)00010-4
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Development of drug resistance is one of the major reasons for the failure of antiretroviral therapy of HIV-1 infection. Knowing the drug sensitivity-resistance profile of viruses present in a patient prior to treatment or change in treatment could help to optimize therapy. Objective: Development of a rapid standardized phenotypic HIV-1 drug sensitivity assay for protease (PR) and reverse transcriptase (RT) inhibitors. Design: The PR gene (codons 1-99) and the 5' part of the RT gene (codons 1-300) of HIV-1 is amplified from the plasma of infected individuals by RT-PCR and ligated into a proviral clone of HIV-1 containing a deletion of the PR gene and the 5' part of the RT gene. Bacteria are transformed with the ligation product and plasmid DNA is prepared from a library of transformed bacteria. The plasmid DNA. is transfected into 293 T cells and recombinant virus is harvested from the supernatant of the transfected cells 2 days after transfection. The sensitivity of the recombinant virus is determined with the help of a sensitive indicator cell line. Results: Recombinant viruses were generated with high efficiency. Determination of the drug sensitivity of the recombinant viruses with an indicator cell line was highly reproducible. The recombinant viruses accurately reflected the sensitivity-resistance profile of the parental viruses. The phenotypic drug sensitivity determined by this assay correlated well with the treatment history of patients. Conclusion: This assay system should allow rapid, high-throughput analyses of phenotypic HIV-I drug sensitivity for PR and RT inhibitors. Due to the efficient generation of recombinant viruses, propagation of the recombinant viruses in cell culture is not required prior to the determination of the sensitivity of the recombinant viruses. The risk of selecting fitter non-resistant viruses due to culture conditions is minimized. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:71 / 80
页数:10
相关论文
共 17 条
  • [1] TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-INFECTED CELLS WITH COMBINATIONS OF HIV-1-SPECIFIC INHIBITORS RESULTS IN A DIFFERENT RESISTANCE PATTERN THAN DOES TREATMENT WITH SINGLE-DRUG THERAPY
    BALZARINI, J
    KARLSSON, A
    PEREZPEREZ, MJ
    CAMARASA, MJ
    TARPLEY, WG
    DECLERCQ, E
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (09) : 5353 - 5359
  • [2] Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay
    Boucher, CAB
    Keulen, W
    vanBommel, T
    Nijhuis, M
    DeJong, D
    DeJong, MD
    Schipper, P
    Back, NKT
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) : 2404 - 2409
  • [3] IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS
    CONDRA, JH
    SCHLEIF, WA
    BLAHY, OM
    GABRYELSKI, LJ
    GRAHAM, DJ
    QUINTERO, JC
    RHODES, A
    ROBBINS, HL
    ROTH, E
    SHIVAPRAKASH, M
    TITUS, D
    YANG, T
    TEPPLER, H
    SQUIRES, KE
    DEUTSCH, PJ
    EMINI, EA
    [J]. NATURE, 1995, 374 (6522) : 569 - 571
  • [4] Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type β-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. -: J Antimicrob Chemother 1998; 42:269-270
    Vahaboglu, H
    Saribas, S
    Akbal, H
    Ozturk, R
    Yucel, A
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) : 269 - 270
  • [5] Johnson V.A., 1990, Techniques in HIV-Research, P71
  • [6] RECOMBINANT VIRUS ASSAY - A RAPID, PHENOTYPIC ASSAY FOR ASSESSMENT OF DRUG SUSCEPTIBILITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES
    KELLAM, P
    LARDER, BA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (01) : 23 - 30
  • [7] A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine
    Kemp, SD
    Shi, CF
    Bloor, S
    Harrigan, PR
    Mellors, JW
    Larder, BA
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (06) : 5093 - 5098
  • [8] CONVERGENT COMBINATION THERAPY CAN SELECT VIABLE MULTIDRUG-RESISTANT HIV-1 IN-VITRO
    LARDER, BA
    KELLAM, P
    KEMP, SD
    [J]. NATURE, 1993, 365 (6445) : 451 - 453
  • [9] Resistance-associated loss of viral fitness in human immunodeficiency virus type 1:: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
    Mammano, F
    Petit, C
    Clavel, F
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (09) : 7632 - 7637
  • [10] ANALYSIS OF RESISTANCE TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE INHIBITORS BY USING MATCHED BACTERIAL EXPRESSION AND PROVIRAL INFECTION VECTORS
    MASCHERA, B
    FURFINE, E
    BLAIR, ED
    [J]. JOURNAL OF VIROLOGY, 1995, 69 (09) : 5431 - 5436